SLC6A3 and depressive symptom measurement: One trial sought to harness the DAT inhibition of bupropion to promote dopamine neurotransmission within classic reward circuitry (ventral striatum to ventromedial prefrontal cortex) for patients with anhedonic depression and elevated CRP; however, there appeared to be no separation from the active comparator (escitalopram; NCT04352101).